Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Cross Below Fifty Day Moving Average - Time to Sell?

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.66 and traded as low as $0.59. Adaptimmune Therapeutics shares last traded at $0.62, with a volume of 1,456,842 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. StockNews.com lowered Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 14th. Mizuho decreased their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a research note on Wednesday, November 27th. Guggenheim cut their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright decreased their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $2.79.

Adaptimmune Therapeutics Stock Down 5.3 %

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The firm has a market cap of $158.62 million, a price-to-earnings ratio of -2.82 and a beta of 2.24. The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.91.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently modified their holdings of the company. Long Focus Capital Management LLC lifted its holdings in Adaptimmune Therapeutics by 15.6% during the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company's stock valued at $12,037,000 after purchasing an additional 1,662,184 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company's stock valued at $15,944,000 after acquiring an additional 1,626,657 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics in the third quarter worth approximately $95,000. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock worth $1,742,000 after purchasing an additional 394,566 shares in the last quarter. Finally, FMR LLC lifted its holdings in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after purchasing an additional 50,419 shares in the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.